ZBH vs SNN stock comparison
Zimmer Biomet vs. Smith & Nephew · data as of November 13, 2026
Zimmer Biomet (ZBH) has a market value of about $19.5B, Smith & Nephew (SNN) about $13.1B. Over their latest twelve months Zimmer Biomet had revenue of $8.6B and Smith & Nephew $6.3B.
On our five checks Smith & Nephew scores higher: 2.6 out of 5 (average) against 2.2 (weak).
By area, the stronger company is Smith & Nephew on value; Smith & Nephew on future growth; Zimmer Biomet on shareholder returns.
Smith & Nephew is cheaper on earnings (P/E 21.3 vs. 26.1).
Zimmer Biomet leads on 9 of the compared lines and Smith & Nephew on 12.
Side by side
| ZBH | SNN | |
|---|---|---|
| Size and price | ||
| Market cap | $19.5B | $13.1B |
| Share price | $103.21 | $31.28 |
| Score | ||
| Overall score (of 5) | 2.2 | 2.6 |
| Value | 1 | 3 |
| Future growth | 1 | 2 |
| Track record | 1 | 1 |
| Financial health | 3 | 3 |
| Shareholder returns | 5 | 4 |
| Valuation | ||
| P/E (TTM) | 26.1 | 21.3 |
| Forward P/E | 11.4 | 13.3 |
| Price / free cash flow | 11.9 | 15.3 |
| Price / sales | 2.3 | 2.1 |
| EV / EBITDA | 11.7 | 11.3 |
| PEG | — | 3.07 |
| DCF value vs. price | −12% | −17% |
| Business | ||
| Revenue | $8.6B | $6.3B |
| Net income | $767M | $635M |
| Free cash flow | $1.6B | $855M |
| Net margin | 9.0% | 10.1% |
| Gross margin (5-yr avg.) | 71.0% | 69.5% |
| ROIC (5-yr avg.) | 4.8% | 6.1% |
| Growth | ||
| Revenue growth (1 yr) | 7.2% | 6.1% |
| Revenue growth (5 yrs, per year) | 6.1% | 6.2% |
| EPS growth (5 yrs, per year) | — | 6.9% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$7.1B | -$2.6B |
| Dividend yield | 0.93% | 2.54% |
| Shareholder yield | 3.4% | 6.4% |
| Analysts | ||
| Upside to average target | +13% | +6% |
| Consensus rating | Buy | Hold |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: ZBH TTM to September 30, 2026, SNN TTM to June 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Zimmer Biomet or Smith & Nephew?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Smith & Nephew scores 2.6 out of 5 and Zimmer Biomet 2.2; the table shows where each one is stronger.
Is Zimmer Biomet cheaper than Smith & Nephew?
On trailing earnings, Smith & Nephew trades at a P/E of 21.3 and Zimmer Biomet at 26.1, so Smith & Nephew is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Zimmer Biomet or Smith & Nephew?
Over five years Smith & Nephew grew revenue about 6.2% a year and Zimmer Biomet about 6.1% a year.
Which pays a higher dividend?
Zimmer Biomet yields 0.93% and Smith & Nephew 2.54%.
Full Zimmer Biomet analysis → Full Smith & Nephew analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.